XW01329Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

  • Billable / Specific Code
ICD-10-PCS XW01329
CMS Source: FY 2027 ICD-10-PCS dataset. Effective Oct 1, 2026 – Sep 30, 2027.FacebookXLinkedInPrint

XW01329 is a billable ICD-10-PCS procedure code for Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. The Alphabetic Index lists this code under Talquetamab Antineoplastic. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Chemotherapy.

Code Identity

ICD-10-PCS Code
XW01329
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
Short Description
Introduce Talquetamab in Subcu, Perc, New Tech 9
Parent Code

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation0Introduction
4BodyPart1Subcutaneous Tissue
5Approach3Percutaneous
6Device/Substance/Technology2Talquetamab Antineoplastic
7Qualifier9New Technology Group 9

In the ICD-10-PCS Alphabetic Index

The FY 2027 ICD-10-PCS Alphabetic Index refers to XW01329 as Talquetamab Antineoplastic. These index entries lead to this code:

Direct entry for this code
New Technology, Talquetamab Antineoplastic
Direct entry for this code
Anatomy or device term that leads here
Leads to this code's table
Leads to this code's table
Leads to this code's table
Leads to this code's table
Leads to this code's table
Leads to this code's table
Leads to this code's table
Leads to this code's table
Leads to this code's table
Leads to this code's table
Leads to this code's table
Leads to this code's table

To code talquetamab antineoplastic, open the FY 2027 ICD-10-PCS Alphabetic Index at Talquetamab Antineoplastic. The entry lists XW01329 directly as a complete, billable code.

Browse the full ICD-10-PCS Alphabetic Index →

Clinical Classification (CCSR)

AHRQ groups this procedure code into these clinical categories.

ADM012
Chemotherapy
Clinical domain: Administration of Therapeutic Substances

Code History

Replaces previously assigned code(s):
  • 3E01305 — Introduction of Oth Antineoplastic into Subcu, Perc Approach

Similar Procedure Codes

Questions About XW01329

Is XW01329 a billable code?

Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 on inpatient claims from October 1, 2026 through September 30, 2027.

What is the ICD-10-PCS code for talquetamab Antineoplastic?

The ICD-10-PCS Alphabetic Index lists Talquetamab Antineoplastic under code XW01329, Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9, billable on inpatient claims in fiscal year 2027.

What do the characters in XW01329 mean?

The code breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 1 is the BodyPart (Subcutaneous Tissue); the 5th character 3 is the Approach (Percutaneous); the 6th character 2 is the Device/Substance/Technology (Talquetamab Antineoplastic); the 7th character 9 is the Qualifier (New Technology Group 9).